Objectives: Multidrug resistance 1 (MDR1) encodes a protein called P-glycoprotein (P-gp), which serves as an efflux pump membrane protein implicated in intestinal homeostasis and drug resistance. Cyclooxygenase-2 (COX2) is a key enzyme in the synthesis of proinflammatory prostaglandins, tumourigenesis and in mucosal defence. Despite the importance of MDR1 and COX2, changes in their mRNA levels have not been studied in cats with inflammatory bowel disease (IBD) and low-grade alimentary lymphoma (LGAL). The present study aimed to determine the mRNA levels of MDR1 and COX2 in cats with IBD and LGAL, and to evaluate their correlation with clinical signs, histological severity and between genes. Methods: Cats diagnosed with IBD (n = 20) and LGAL (n = 9) between 2008 and 2015 were included in the current study. Three healthy animals composed the healthy control cats group in which endoscopy was performed immediately before the ovariohysterectomy. All duodenal biopsy samples were obtained by endoscopy. Feline chronic enteropathy activity index was calculated for all cases. IBD histopathology was classified according to severity. MDR1 and COX2 mRNA levels were determined by absolute reverse transcriptase-quantitative real-time PCR. Results: Statistically significant differences were observed for MDR1 and COX2 mRNA levels between the IBD and LGAL groups. No correlations were observed between molecular gene expression, feline chronic enteropathy activity index and histological grading for IBD, and between MDR1 and COX2 genes. However, a positive statistically significant correlation was observed between MDR1 and COX2 expression in the duodenum of cats. Conclusions and relevance: MDR1 and COX2 gene expression is increased in cats with LGAL compared with cats with IBD. The control group tended to have lower values than both diseased groups. These results suggest that these genes may be involved in the pathogenesis of IBD or LGAL in cats.
Cyclooxygenase 2 (COX-2) is an inducible isoform by cellular activation, proinflammatory cytokines and growth factors. The aims of the current study were to evaluate COX-2 immunoexpression in epithelial and lamina propria (LP) of cats with inflammatory bowel disease (IBD) and low grade alimentary lymphoma (LGAL), as well as to correlate them with clinical signs and histopathological scoring. Cats diagnosed with IBD and LGAL (2007–2013) were included in the current study. Feline chronic enteropathy activity index (FCEAI) was calculated for all cases. Control group was composed by 3 healthy indoor cats and 5 sick cats died or were euthanized (non-gastrointestinal illness). Diagnosis and classification of IBD and LGAL was established according to the WSAVA gastrointestinal standardization group template and the National Cancer Institute formulation, respectively. Furthermore, a modified WSAVA template was applied for LGAL evaluation. Immunolabelling for COX-2 (polyclonal rabbit anti-murine antibody) was performed on biopsy samples. Epithelial and LP (inflammatory or neoplastic cells) COX-2 immunolabelling was calculated according to the grade and intensity. The most representative segment scored by the WSAVA and the modified WSAVA were used for statistical analysis. Significant difference was found regarding COX-2 intensity overexpression in the epithelial cells of IBD and LGAL groups when compared to control cats, but not between the groups of sick cats, whereas no differences were found regarding the grade of immunoreactivity between groups. No difference was found for COX-2 immunoexpression at the LP between all groups. However, 3 cats from LGAL group showed COX-2 expression in neoplastic cells at the LP. There were no correlations between epithelial or LP COX-2 expression and FCEAI and histological alterations. Increased COX-2 intensity at the epithelial cells observed in cats with IBD and LGAL may be secondary to the inflammatory response or a protective function in the intestinal reparation. COX-2 expression at the LP was presented in 33% of LGAL. This result provides a reason for further investigation concerning the role of COX-2 expression in feline alimentary lymphoma.
Background: Meglumine antimoniate is used to treat canine leishmaniosis. In humans, it has been associated with pancreatitis. Although a few case reports have described acute pancreatitis secondary to antimonial treatment in dogs, some studies have concluded that pancreatitis is not an adverse effect of this medication. The objective was to evaluate whether treatment with meglumine antimoniate could induce pancreatitis in dogs with leishmaniosis, on the basis of clinical signs, canine serum specific quantitative pancreatic lipase immunoreactivity (cPLI) concentration, and ultrasonographic abnormalities. Methods: A prospective, observational, longitudinal, and multicentric study was conducted from April 2021 through February 2023. Results: A total of 33 dogs with leishmaniosis were included and classified into LeishVet clinical stages; 13 (39.4%) were included in stage II, 11 (33.3%) in stage III, and 9 in stage IV (27.3%). and 14 (42.4%) developed pancreatitis, 10 during treatment with meglumine antimoniate, and 4 at the end of the treatment. Advanced LeishVet clinical stage was statistically associated with development of pancreatitis. In addition, nine dogs received prednisone at the beginning of treatment, but it was not statistically associated with the prevention of pancreatitis. Conclusions: Meglumine antimoniate remains the first line leishmanicidal treatment option for canine leishmaniosis, but it appears to induce pancreatitis in a significant percentage of dogs. Monitoring serum cPLI levels and performing an abdominal ultrasound should be considered when pancreatitis-associated clinical signs are observed, or when there is a high suspicion of circulating immune complexes in dogs with advanced LeishVet clinical stage. Graphical
A 10‐year‐old, male neutered domestic shorthair cat was referred for reddish discolouration of its abdominal skin with serosanguineous discharge. The affected skin was bruised, nodular and had fluid‐filled cavities. It was painful on palpation. A final diagnosis of lymphangiosarcoma was made by prospero‐related homeobox gene‐1 (PROX‐1) immunohistochemistry. Metronomic chemotherapy treatment was instaured with toceranib phosphate, chlorambucil and meloxicam. Partial remission was achieved at 18 days and stable disease was maintained for 36 days (survival time: 54 days). Afterward, the tumour began to regrow aggressively and the patient developed anorexia; owners elected for euthanasia. Total survival time achieved was 63 days. To the authors’ knowledge, this is the first case report of feline caudoventral abdominal lymphangiosarcoma treated with metronomic chemotherapy.
The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII) are derived hematological indices reflecting systemic inflammatory balance in dogs with different serological statuses for canine leishmaniosis (CanL). The aim of this study was to describe and compare hematological ratios (HRs) between dogs seropositive and seronegative for Leishmania infantum and to assess their distribution across LeishVet stages. A retrospective multicenter case–control study was conducted, including 305 seropositive dogs and 305 seronegative controls from referral hospitals in Spain. Hematological data were retrospectively reviewed and analyzed. Significant differences were observed in NLR and MLR between seronegative control dogs and dogs with leishmaniosis, whereas no differences were found for PLR or SII. Median NLR and MLR values were higher in dogs with leishmaniosis compared to controls. In addition, comparisons across LeishVet stages revealed statistically significant differences for all evaluated HRs. These findings indicate that NLR and MLR are increased in dogs with CanL and that HR varies across LeishVet stages, as these indices represent the relative proportions of neutrophils and monocytes in relation to lymphocytes; therefore, changes in their values reflect shifts in leukocyte distribution observed across clinical stages.